Skip to main content
Clinical Trials/NCT04498065
NCT04498065CompletedNot Applicable

MYocardial DOmmages Related to COVID-19

Centre Hospitalier Universitaire Dijon1 site in 1 country273 target enrollmentStarted: March 1, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
273
Locations
1
Primary Endpoint
characterize the myocardial damage associated with CoV-2 SARS infection

Study Overview

Brief Summary

Myocardial injury, as assessed by elevation of cardiac troponins (Tnc), is frequent among patients with COVID-19. Although rare autopsy cases reported COVID-19 related myocardial inflammation, the origin of Tnc elevation is unknown to date. Several cardiac causes, such as myocarditis, non-ischemic myocardial injury (NIMI), or myocardial infarction (MI) may lead to Tnc kinetic. Our work will test the hypothesis that during SARS-Cov2 infection, the elevation of cardiac biomarkers could be linked to the occurrence of myocarditis.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • COVID-19 positive patient hospitalized < 72 h after symptoms onset with troponin assessement.

Exclusion Criteria

  • patients hospitalized > 72h after symptom onset

Outcomes

Primary Outcomes

characterize the myocardial damage associated with CoV-2 SARS infection

Time Frame: Through study completion, an average of 2 years

Myocardtitis diagnosis in patients COVID+ and troponin+

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

MYocardial DOmmages Related to COVID-19 | Clinical Trial